Microbody proliferation in liver induced by nafenopin, a new hypolipidemic drug: Comparison with CPIB

Janardan Reddy*, Donald Svoboda, Daniel Azarnoff

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

50 Scopus citations

Abstract

Nafenopin (2-methyl-2[P-(1,2,3,4-tetrahydro-1 naphthyl) phenoxy]- propionic acid, a phenolic ether with hypolipidemic properties, when administered by gavage at 100 mg/kg b wt daily for 1 to 2 weeks, caused a significant increase in the number of microbody profiles and simultaneous increase in catalase activity in livers of male rats. The concentration of catalase protein and the rate of incorporation of H3-δ-aminolevulinic acid into catalase fraction, as determined by immunochemical methods were approximately twice that of controls. The microbody proliferation resulting from nafenopin treatment was comparable to that induced by CPIB.

Original languageEnglish (US)
Pages (from-to)537-543
Number of pages7
JournalBiochemical and Biophysical Research Communications
Volume52
Issue number2
DOIs
StatePublished - May 15 1973

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'Microbody proliferation in liver induced by nafenopin, a new hypolipidemic drug: Comparison with CPIB'. Together they form a unique fingerprint.

Cite this